Combining Selank with BPC-157 and TB-500

A common pattern in peptide research communities is combining a tissue-repair compound, typically BPC-157 or TB-500, with a neurologically targeted one such as Selank. The question that follows is straightforward: are these safe to use at the same time, and does the combination change the effect of either? The honest answer is that no published human study has tested any of these three together, and no pharmacokinetic data exists for the combination. What we can do is explain what each compound is, what its evidence base actually shows, and where the genuine unknowns lie.

What Selank is and what the evidence base looks like

Selank is a synthetic heptapeptide (sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as an analogue of tuftsin, a naturally occurring tetrapeptide with immunomodulatory properties. It has been studied primarily in Russian clinical settings for anxiety disorders. The best available published trials are small and limited to patients with diagnosed anxiety conditions. A comparative study by Medvedev and colleagues (PMID 25176261) enrolled 60 patients with phobic-anxiety and somatoform disorders and found that Selank produced pronounced anxiolytic effects with a mild nootropic profile^[1]. A second study (PMID 26356395) tested combined Selank plus phenazepam against phenazepam alone and found the combination reduced several benzodiazepine side effects, including sedation and attention impairment^[2].

The pharmacology points to two primary mechanisms: inhibition of enkephalin-degrading enzymes (prolonging the availability of enkephalins in circulation) and modulation of GABA and NMDA receptor gene expression depending on the route of administration. Selank is not approved as a medicine by the FDA, the EMA, the MHRA, or any national agency in the EU or EEA. It is sold online as a research chemical and circulates entirely through grey-market channels.

BPC-157 and TB-500: the repair-focused peptides

BPC-157 is a 15-amino-acid synthetic fragment studied almost entirely in rodents for tendon, gut, and brain-repair effects. Human evidence is essentially absent: there is no published randomised controlled trial for any indication. TB-500 is a label applied commercially to either full-length thymosin beta-4 (a 43-residue G-actin sequestering protein with preclinical literature on angiogenesis, cardiac protection, and tissue repair) or its synthetic heptapeptide fragment AC-LKKTETQ. Neither compound is authorised as a medicine anywhere. Both sit on the WADA Prohibited List: BPC-157 under S0 (non-approved substances) and TB-500 under S2 (peptide hormones, growth factors and related substances). The US Department of Defense's Operation Supplement Safety has published explicit guidance that BPC-157 is an unapproved drug^[3].

Can they be combined? What the literature does and does not say

The mechanisms of these three compounds are distinct: Selank acts on enkephalinase, GABA receptors, and monoamine systems in the central nervous system; BPC-157 is proposed to act on angiogenesis pathways and gut-brain axis signalling in peripheral tissue; TB-500 (as full thymosin beta-4) acts on G-actin sequestration and cell migration. There is no published human pharmacokinetic study of any pair of them, let alone all three. The absence of a known interaction is not evidence of safety. It means the interaction question is simply unanswered.

From a practical standpoint, there is no published evidence that subcutaneous administration of Selank alongside BPC-157 or TB-500 produces any additive or opposing pharmacological effect in humans. The compounds have different targets and different half-lives. Community reports of simultaneous use exist but do not constitute controlled data. Any claim that the combination amplifies results or that a half-dose of each is equivalent to a full dose of either is speculation, not pharmacology.

Retatrutide is in a different category

Retatrutide is an investigational triple GLP-1, GIP, and glucagon receptor agonist from Eli Lilly. Its Phase 2 trial (Jastreboff et al., NEJM 2023) reported 24.2% mean weight loss at 48 weeks on the 12 mg dose^[4]. Phase 3 TRIUMPH trials are ongoing; the compound is not approved anywhere and cannot lawfully be compounded in the US. The FDA has issued warning letters to compounding pharmacies selling unauthorised retatrutide. Combining retatrutide with BPC-157, TB-500, or Selank is pharmacologically unexplored territory: the three grey-market peptides act on entirely different receptor systems from retatrutide, but none of the relevant combinations has been studied in any controlled setting.

What we do not yet know

There is no human pharmacokinetic data for any of these combinations. There are no published safety data for simultaneous use of Selank with BPC-157 or TB-500, or for any of them alongside retatrutide. The available human trials of Selank were all conducted in patients with anxiety disorders, not in people who were also using tissue-repair peptides. What is known about BPC-157 and TB-500 comes almost entirely from rodent models, and those models do not address polypharmacy scenarios. For a broader view of where each compound sits regulatory-wise, see the BPC-157 peptide page and the retatrutide peptide page.

If you are considering any combination of unapproved peptides, consult a healthcare provider who can review your full medical history. The absence of published drug-drug interaction data for grey-market compounds is not reassuring; it simply means no one has studied the question rigorously.